Changes in Quality of Life and Related Factors in Thyroid Cancer Patients with Radioactive Iodine Remnant Ablation

2013 ◽  
Vol 43 (6) ◽  
pp. 801 ◽  
Author(s):  
Seon Hee Yoo ◽  
Smi Choi-Kwon
2019 ◽  
Vol Volume 11 ◽  
pp. 10593-10598 ◽  
Author(s):  
Jie Li ◽  
Ling Bo Xue ◽  
Xiao Yi Gong ◽  
Yan Fang Yang ◽  
Bu Yong Zhang ◽  
...  

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Umesh Jayarajah ◽  
Mahilal Wijekoon ◽  
Sanjeewa A. Seneviratne

Abstract Background Radioactive iodine (RAI) therapy is the standard adjuvant treatment for differentiated thyroid cancer (i.e. papillary and follicular). RAI is associated with troublesome early, intermediate and late adverse effects. Although glucocorticoids are used for the management of these adverse effects, there is little evidence regarding the effectiveness of prophylactic glucocorticoids to prevent these complications. This trial will evaluate the efficacy of a short course of prophylactic glucocorticoids in the prevention of adverse effects of RAI treatment in patients with differentiated thyroid cancer. Methods A phase II/III, single-centre, randomized, double-blinded, placebo-controlled, parallel-arm clinical trial will be conducted. Patients with differentiated thyroid cancer who are referred to RAI therapy at the National Cancer Institute, Sri Lanka, will be randomized into two arms consisting of 200 patients each. The experimental group will receive prophylactic oral prednisolone 0.5 mg/kg and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral prednisolone 0.5 mg/kg and omeprazole 20 mg daily for 3 days. The control group will receive oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days. Clinically significant adverse effects assessed as related to RAI as well as prednisolone therapy and the quality of life parameters will be compared between the two groups. Discussion If proven beneficial, this intervention can be incorporated into the standard practice to reduce early and intermediate adverse effects of RAI for thyroid cancer with a potential improvement of quality of life. Trial registration Sri Lanka Clinical Trials Registry SLCTR/2020/009. Registered prospectively on 23 February 2020. Items of the WHO Trial Registration Data Set are provided in the supplementary file.


2015 ◽  
Vol 19 (3) ◽  
pp. 292-300 ◽  
Author(s):  
Nai-Wen Chang ◽  
Kuan- Chia Lin ◽  
Wen-Hu Hsu ◽  
Shih-Chun Lee ◽  
James Yi-Hsin Chan ◽  
...  

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6606-6606
Author(s):  
G. de Pouvourville ◽  
I. Borget ◽  
M. Allyn ◽  
M. Schlumberger

6606 Background: In thyroid cancer patients, follow-up is designed to detect recurrent disease and consists of neck- ultrasonography (US), thyroglobulin measurement (Tg) and radioiodine whole body scan (WBS). Recent guidelines have restricted the use of WBS to suspicious cases. To insure diagnostic accuracy, follow-up control requires TSH stimulation, either with thyroid hormone withdrawal (THW) or rhTSH, which have demonstrated similar diagnostic accuracy. THW induces significant morbidity associated with hypothyroidism, leading to a decrease in patient quality of life and ability to work, whereas rhTSH is an innovative costly drug that avoids such patient burden. A societal cost-utility analysis was conducted to compare 4 follow-up strategies, combining a method of stimulation (rhTSH or THW) and a testing protocol (US+Tg+WBS or US+Tg alone). Methods: A Markov model was built to describe the follow-up of thyroid cancer patients first treated by thyroidectomy and radioiodine ablation, over 5 years. Estimates for diagnostic accuracy values and recurrence rate were extracted from a French multicenter randomized trial. Costs were computed from the perspective of the society, including medical resources consumed (hospitalisation, rhTSH, tests, treatment of recurrence). The model also incorporated the benefits of rhTSH in terms of quality of life (utility scores derived from SF36) and the reduction in duration and overall cost of sick leave. Results: Among the 753 patients included, 13 patients presented recurrence. rhTSH stimulation resulted in a higher utility score (0.802 vs. 0.637) over the period of stimulation and a reduction of 1083 € of absenteeism costs in active patients. As compared to the THW+Tg+US+WBS strategy, the incremental cost-utility ratios (ICER) showed economic dominance for the rhTSH strategies with ratios of −16,876 and −19,297 €/QALY with and without WBS respectively. The ICER for the strategy THW+US+Tg reached 29,333 €/QALY, as compared to THW+Tg+US+WBS strategy. Conclusions: the recommended strategy combining Tg determination and US after rhTSH stimulation appears the most cost-effective in the follow-up of thyroid cancer patients, as it is the strategy the less costly and associated with improved patient quality of life. No significant financial relationships to disclose.


2015 ◽  
Vol 42 (8) ◽  
pp. 1179-1188 ◽  
Author(s):  
Eva-Maria Gamper ◽  
Lisa M. Wintner ◽  
Margarida Rodrigues ◽  
Sabine Buxbaum ◽  
Bernhard Nilica ◽  
...  

2020 ◽  
Vol 38 (2) ◽  
pp. 1-8
Author(s):  
AKM Farhad Hossain ◽  
Md Ziaul Islam ◽  
Sayada Fatema Khatun

Background: Having the longevity of thyroid cancer patients, any impairment in health-related quality of life (HRQOL) during the follow-up period is of great importance. Objective: The study was conducted to determine the health related quality of life of thyroid cancer patients. Material and methods: This cross sectional study was conducted among 246thyroid cancer patients. Data were collected by face-to-face interview and reviewing medical records with semi-structured questionnaire and checklist with validated scale. The subjects were purposively selected following specific selection criteria and maintaining ethical issues. Place and period of study: The study was conducted during the period from July 2018-June 2019 in two tertiary hospitals of Dhaka city: Bangabandhu Sheikh Mujib Medical University and Dhaka Medical College Hospital, Dhaka. Results: This study revealed that majority (74.4%) of respondents was female, married (72%), housewife (61.4%), rural respondent (41.1%) and had primary education (69%). Mean (± SD) age of the respondent was 37.85(±12.20) years (range 14-70 years) and mean (± SD) monthly family income was Tk.17681(±10602). Out of 246 cases, 204 (82.9%) was papillary and 42 (17.1%) was follicular carcinoma. Main presenting features were neck swelling (91.5%), swollen lymph node (41.9%), dysphonia (57.3%) and dysphagia (35.4%). Mean (± SD) of total HRQOL score was 73.7 ± 8.39. HRQOL score of students and higher educated patients were better among the respective groups (p <.001). The study showed the association of HRQOL with clinical condition of thyroid cancer patients (R2=.025). HRQOL revealed the strong prediction with education (β=-0.888, p<.05), family income (β=0.05, p<.05), marital status (β=-0.1.384, p<.05), clinical condition (β=-0.522, p<.05) and perceived stress (β=-0.632, p<.001). Conclusion: The overall HRQOL score was considerably good in this study. Timely detection, regular motivation and attending clinical condition may significantly improve the HRQOL of thyroid cancer patients JOPSOM 2019; 38(2): 1-8


2021 ◽  
Vol 233 (5) ◽  
pp. S66
Author(s):  
Mariam N. Ali-Mucheru ◽  
Sarah E. Robbins ◽  
Cameron L. Macdonald ◽  
Nadine P. Connor ◽  
Rebecca S. Sippel

Sign in / Sign up

Export Citation Format

Share Document